Sustainable Microcrystalline Cellulose (MCC) Production

Our newly opened Lappeenranta, Finland production facility powered by our patented AaltoCell™ technology represents a breakthrough in sustainable MCC production. Our commitment to environmental stewardship and innovative process optimization has resulted in a product with the lowest GWP and overall environmental impact in the industry. The primary purpose of Nordic Bioproducts Group’s AaltoCell™ technology is to revolutionize the production of Microcrystalline Cellulose (MCC) by significantly reducing its carbon footprint. Traditional MCC production processes are energy-intensive and potentially environmentally detrimental, whereas AaltoCell™ offers an eco-friendly alternative with continuous production, enhancing both efficiency and sustainability. Our technology addresses the critical market need for greener pharmaceutical manufacturing processes, aligning with the industry’s shift towards sustainability. AaltoCell™ technology leverages an optimized and advanced hydrolysis technology that minimizes energy consumption and reduces the use of water and harmful chemicals. Additionally, due to its continuous production process, this innovation results in a higher yield and quality of MCC while maintaining cost-effectiveness. Our approach supports pharmaceutical companies in meeting stringent regulatory standards and market demands for sustainable products. By providing a cleaner, greener solution, AaltoCell™ enables the Pharma industry to advance towards a more sustainable future.